| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
BI-1622 (0–5 µM, 72–96 hours) prevents HER2-dependent cell lines from proliferating [1]. In NCI-H2170 HER2YVMA and PC-9 HER2YVMA cells, BI-1622 causes a dose-dependent decrease in pHER2 and pERK levels, which is accompanied by a decrease in DUSP6 messenger RNA levels [1]. Good permeability and no propensity for PgP-mediated efflux are displayed by BI-1622 [1]. In vitro clearance of BI-1622 in mice liver microsomes and mouse hepatocytes is excellent [1].
|
|---|---|
| ln Vivo |
BI-1622 (1 mg/kg IV; 10 and 100 mg/kg PO; once) indicated moderate clearance, moderate volume of distribution, and good to moderate bioavailability [1]. BI-1622 (0-100 mg/kg, orally, twice day) reduces tumor development and suppresses oncogenic signaling in vivo [1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Ba/F3 Cell Tested Concentrations: 0-5 µM Incubation Duration: 72 hrs (hours) or 96 hrs (hours) Experimental Results: Effective inhibition of proliferation of cancer cell lines dependent on amplified HER2 or NRG-1 fusions. Inhibits different HER2 oncogenic variants and HER2WT in tumor cell lines with IC50 values below 50 nM while sparing EGFRWT-driven cells. |
| Animal Protocol |
Animal/Disease Models: Female NMRI-Foxn1nu (nude) mice (6-8 weeks old, 8-10 mice per cage, subcutaneously (sc) (sc) transplanted with PC-9 HER2YVMA, NCI-H2170 HER2YVMA or NCI-N87 cells) [1]
Doses: 10, 30 and 100 mg/kg Dosing: PO twice (two times) daily Experimental Results: In the NCI-H2170 HER2YVMA mechanistic model, BI-1622 at 100 mg/kg twice (two times) daily resulted in delayed tumor growth (73% TGI). In the ST3107 HER2 exon 20 mutation model, both BI-4142s (100 mg/kg twice (two times) daily) resulted in tumor regression. Animal/Disease Models: NMRI Foxn1nu (nude) mice (n=3 per group) [1] Doses: 1 mg/kg (IV); 10 and 100 mg/kg (oral) Route of Administration: IV, oral; once (pharmacokinetic/PK/PKs Analysis) Experimental Results: demonstrated moderate body clearance (50% hepatic blood flow), moderate volume of distribution, and good to moderate bioavailability up to 68%. |
| References |
| Molecular Formula |
C26H24N10O2
|
|---|---|
| Molecular Weight |
508.534563064575
|
| Exact Mass |
508.208
|
| CAS # |
2681392-19-6
|
| PubChem CID |
156821237
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
2.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
826
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(N1CCN(C2=NC=C3N=CN=C(NC4=CC=C(OC5C=CN6N=CN=C6C=5)C(C)=C4)C3=N2)CC1)(=O)C=C
|
| InChi Key |
KXUBSQUYDKKQTR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H24N10O2/c1-3-23(37)34-8-10-35(11-9-34)26-27-14-20-24(33-26)25(30-15-28-20)32-18-4-5-21(17(2)12-18)38-19-6-7-36-22(13-19)29-16-31-36/h3-7,12-16H,1,8-11H2,2H3,(H,28,30,32)
|
| Chemical Name |
1-[4-[4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]pyrimido[5,4-d]pyrimidin-6-yl]piperazin-1-yl]prop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~196.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9665 mL | 9.8323 mL | 19.6645 mL | |
| 5 mM | 0.3933 mL | 1.9665 mL | 3.9329 mL | |
| 10 mM | 0.1966 mL | 0.9832 mL | 1.9665 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
